Insider Selling: Enfusion, Inc. (NYSE:ENFN) Insider Sells 3,126 Shares of Stock

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 3,126 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $35,573.88. Following the transaction, the insider now directly owns 221,875 shares of the company’s stock, valued at approximately $2,524,937.50. This represents a 1.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Bronwen Bastone also recently made the following trade(s):

• On Monday, March 3rd, Bronwen Bastone sold 2,064 shares of Enfusion stock. The shares were sold at an average price of $11.48, for a total transaction of $23,694.72.
• On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total transaction of $8,195.17.

Enfusion Stock Performance

ENFN opened at $11.24 on Monday. The firm has a 50 day moving average price of $10.98 and a 200 day moving average price of $9.90. The company has a market cap of $1.44 billion, a PE ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80.

Enfusion (NYSE:ENFN) last issued its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The firm had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. On average, sell-side analysts predict that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Institutional Trading of Enfusion

Several large investors have recently bought and sold shares of the company. New York State Common Retirement Fund grew its position in Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock valued at $19,848,000 after acquiring an additional 370,498 shares in the last quarter. Geode Capital Management LLC grew its position in Enfusion by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 1,050,549 shares of the company’s stock valued at $10,823,000 after acquiring an additional 21,183 shares in the last quarter. Wellington Management Group LLP grew its position in Enfusion by 6.1% in the fourth quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company’s stock valued at $10,671,000 after acquiring an additional 59,700 shares in the last quarter. Azora Capital LP grew its position in Enfusion by 3,255.9% in the fourth quarter. Azora Capital LP now owns 1,000,967 shares of the company’s stock valued at $10,310,000 after acquiring an additional 971,140 shares in the last quarter. Finally, State Street Corp grew its position in Enfusion by 2.3% in the third quarter. State Street Corp now owns 952,895 shares of the company’s stock valued at $9,043,000 after acquiring an additional 21,729 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ENFN shares. Stifel Nicolaus upped their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. William Blair reissued a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Piper Sandler increased their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.